Hong Kong's bourse operator has proposed new measures to bolster initial public offerings, a move that is expected to further ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor ...

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence signals.

Beijing Tong Ren Tang Healthcare Investment, a subsidiary of major Hong Kong-listed traditional Chinese medicine group Tong Ren Tang, plans to raise up to HK$897.7 million by offering 108.2 million ...

Detailed price information for Renaissance IPO ETF (IPO-A) from The Globe and Mail including charting and trades.

Gov. Maura Healey is using a new executive order to procure more energy supply and storage in Massachusetts, an effort her ...

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Hong Kong’s capital markets saw a strong finish to 2025, as a wave of strategic innovation drove breakthroughs for the listing and digital asset markets, according to the Securities and Futures ...

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.